ArticleBMC cancer2015
Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Guideline
- Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye.Genes · 2025Article
- [Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma.SAGE open medical case reports · 2023Article
- APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.Lung cancer (Amsterdam, Netherlands) · 2022Article
- Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients withCurrent oncology (Toronto, Ont.) · 2022Review
- Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.BMC cancer · 2022Article
- Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review.Frontiers in immunology · 2022Review
- Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation.OncoTargets and therapy · 2021Article
- Article
- Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study.World journal of oncology · 2019Article
- The relationship between preliminary efficacy and prognosis after first-lineAnnals of translational medicine · 2019Article
- Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns.Journal of global oncology · 2019Article
- Clinical And Imageological Features Of Lung Squamous Cell Carcinoma WithCancer management and research · 2019Article
- Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring AnOncoTargets and therapy · 2019Article
- Efficacy of icotinib in advanced lung squamous cell carcinoma.Cancer medicine · 2018Article
- The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.International journal of clinical oncology · 2018Article
- Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations.OncoTargets and therapy · 2017Review
- New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.OncoTargets and therapy · 2017Review
- EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.Scientific reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough new individual treatments continue to reshape the landscape of clinical care in patients with lung cancer, most of the progress has been mainly of benefit to patients with lung adenocarcinomas rather than squamous cell lung carcinoma (SQCLC). Our study aimed to determine whether the epidermal growth factor receptor (EGFR) gene mutation is present in pure SQCLC. We further determined the mutation frequency and the clinical and pathological features of groups that are in high risk for EGFR mutation.
methodsA total of 185 Chinese patient specimens diagnosed as SQCLC in the Shanghai Chest Hospital at the Shanghai Jiao Tong University were selected for this study. Hematoxylin-eosin stained slides for all cases were reviewed and evaluated by immunohistochemical analysis with the aim of selecting samples with pure SQCLC. After screening, 22 cases were eliminated and 163 pure SQCLC cases remained. Amplification Refractory Mutation System was used to detect the EGFR gene mutation status in the 163 SQCLC specimens.
resultsA total of 28 cases with EGFR mutation were detected among the 163 specimens. The EGFR mutation rate was 17.2% (28/163). Sex and smoking status were significantly associated with the status of EGFR gene mutation (P = 0.022 and P = 0.049, respectively). Age and degree of differentiation were not significantly correlated to EGFR mutation (P = 0.730 and P = 0.651, respectively).
conclusionsEGFR mutations are present in pure SQCLC, which are more frequently detected in females and nonsmoker patients. Our results indicate the importance for all patients with SQCLC to have EGFR mutation status examined. These patients with activating EGFR mutation could accept tyrosine kinase inhibitors (TKIs) treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.